Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
Fiche publication
Date publication
août 2022
Journal
The American journal of gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Danese S, Ferrante M, Feagan BG, Peyrin-Biroulet L, Hibi T, Sandborn WJ, Schreiber S, Ritter T, Loftus EV, Rogler G, Oortwijn A, Yun C, Le Brun FO, Dinoso J, Hsieh J, Vermeire S
Lien Pubmed
Résumé
Patients with ulcerative colitis (UC) regard rapid onset of action among the most important aspects of their treatment. We used partial Mayo Clinic Score (pMCS) and the component patient-reported subscores to assess rapidity and sustainability of response to filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor, in adults with moderately to severely active UC in the phase 2b/3 SELECTION trial. The association between early symptomatic improvements and health-related quality of life (HRQoL) outcomes was also assessed.
Référence
Am J Gastroenterol. 2022 08 23;: